120 W/2 μm铥激光前列腺汽化剜除术治疗BPH的疗效观察

孙江江; 杨龙; 王宝龙; 李黎明; 崔喆

120 W/2 μm铥激光前列腺汽化剜除术治疗BPH的疗效观察

- 天津医科大学总医院泌尿外科(天津, 300052)

详细信息

通讯作者: 崔喆,E-mail:cuizhe9505@sina.com

中图分类号: R697

收稿日期: 2012-10-19

Curative effect of 120 W/2 μm Thulium: YAG laser vapoenucleation of the prostate therapy BPH

- Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China

More Information

Corresponding author: CUI Zhe, E-mail: cuizhe9505@sina.com

Received Date: 19 October 2012

摘要

摘要: 目的：探讨120 W/2 μm铥激光前列腺汽化剜除术（ThuVEP）的安全性及疗效。方法：应用120 W连续波2 μm ThuVEP治疗BPH患者59例，分析患者术前资料及围术期情况，并对相应并发症进行评估。结果：患者平均前列腺体积（59.6±29.6）ml，平均手术时间（96.2±26.9）min，剜除时间（40.6±25.7）min，平均保留尿管时间（5.7±1.0）d。59例术后3个月随访效果良好。手术前后生活质量（QOL）评分为（4.5±1.2）：（1.5±0.9）分，国际前列腺症状（IPSS）评分为（22.5±6.9）：（4.9±1.3）分，最大尿流率为（7.9±4.6）：（25.2±11.3）ml/s，剩余尿量为（148.6±76.5）：（23.5±28.6）ml。2例术后需输血治疗。并发尿道狭窄2例。结论：120 W/2 μm ThuVEP治疗BPH是安全有效的，且并发症较少。
- 前列腺增生 /
- Tm:YAG激光 /
- 铥激光前列腺汽化剜除术
Abstract: Objective: To evaluate the safety and efficacy of 120 W/2 μm Thulium:yttrium-aluminium-garnet(YAG) vapoenucleation of the prostate (ThuVEP) for patients with benign prostate hyperplasia.Method: In total, 59 consecutive patients undergoing ThuVEP at our institution were evaluated prospectively. ThuVEP was carried out using the 120 W/2 μm continuous-wave Tm:YAG laser. Patient perioperative and 3 month follow-up data were analysed. The complications were assessed.Result: Mean preoperative prostate volume was (59.6±29.6) ml. Total operation time averaged(96.2±26.9) min, and the enucleation time was (40.6±25.7) min. The mean catheter time was (5.7±1.0) days. All patients were available for review at the 3-month follow-up mark. Quality of life (4.5±1.2):(1.5±0.9), international prostate symptom score (22.5±6.9):(4.9±1.3), maximum urinary flow rate (7.9±4.6):(25.2±11.3) ml/s and postvoiding residual urine (148.6±76.5):(23.5±28.6) ml. Two patients needed blood transfusions postoperatively. Urethral stricture developed in 2 respectively of the patients.Conclusion: 120 W/2 μm ThuVEP is a safe and efficacious procedure for the treatment of symptomatic benign prostatic obstruction. The incidence of complications with ThuVEP was low.
- benign prostate hyperplasia /
- Tm:YAG laser /
- Thulium vapoenucleation of the prostate

HTML全文

参考文献(15)

[1]	Kuntz R M. Current role of lasers in the treatment of benign prostatic hyperplasia(BPH)[J]. Eur Urol, 2006, 49:961-969.
[2]	Ahyai S A, Gilling P, Kaplan S A, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement[J]. Eur Urol, 2010, 58:384-397.
[3]	Kelly D C, Das A. Holmium laser enucleation of the prostate technique for benign prostatic hyperplasia[J]. Can J Urol, 2012, 19:6131-6134.
[4]	Montorsi F, Naspro R, Salonia A, et al. Holmium laser enucleation versus transurethral resection of the prostate:results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia[J]. J Urol, 2004, 172:1926-1929.
[5]	Hauser S, Rogenhofer S, Ellinger J, et al. Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage[J]. Urol Int, 2012, 88:390-394.
[6]	Bach T, Netsch C, Pohlmann L, et al. Thulium:YAG vapoenucleation in large volume prostates[J]. J Urol, 2011, 186:2323-2327.
[7]	Fu W J, Zhang X, Yang Y, et al. Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate:a prospective nonrandomized trial with 1-year follow-up[J]. Urology, 2010, 75:194-199.
[8]	Bach T, Huck N, Wezel F, et al. 70 vs 120 W thulium:yttrium-aluminium-garnet 2 microm continuous-wave laser for the treatment of benign prostatic hyperplasia:a systematic ex-vivo evaluation[J]. BJU Int, 2010, 106:368-372.
[9]	Naspro R, Bachmann A, Gilling P, et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate[J]. Eur Urol, 2009, 55:1345-1357.
[10]	Matlaga B R, Kim S C, Kuo R L, et al. Holmium laser enucleation of the prostate for prostates of >125 ml[J]. BJU Int, 2006, 97:81-84.
[11]	Wendt-Nordahl G, Huckele S, Honeck P, et al. Systematic evaluation of a recently introduced 2-microm continuous-wave thulium laser for vaporesection of the prostate[J]. J Endourol, 2008, 22:1041-1045.
[12]	Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate:a prospective multicenter evaluation of 10,654 patients[J]. J Urol, 2008, 180:246-249.
[13]	Gratzke C, Schlenker B, Seitz M, et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement:results of a prospective multicenter study[J]. J Urol, 2007, 177:1419-1422.
[14]	Adam C, Hofstetter A, Deubner J, et al. Retropubic transvesical prostatectomy for significant prostatic enlargement must remain a standard part of urology training[J]. Scand J Urol Nephrol, 2004, 38:472-476.
[15]	Shah H N, Mahajan A P, Hegde S S, et al. Peri-operative complications of holmium laser enucleation of the prostate:experience in the first 280 patients, and a review of literature[J]. BJU Int, 2007, 100:94-101.